NASDAQ:TOCA Tocagen (TOCA) Stock Price, News & Analysis → Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad) Free TOCA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.71▼$0.7450-Day Range$1.26▼$41.0352-Week Range$0.42▼$6.77Volume14,300 shsAverage Volume1.47 million shsMarket Capitalization$17.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Tocagen alerts: Email Address Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now About Tocagen Stock (NASDAQ:TOCA)Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.Read More Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now TOCA Stock News HeadlinesDecember 11, 2023 | markets.businessinsider.comRiskOn International And 3 Other Stocks Under $2 Insiders Are BuyingNovember 2, 2023 | finance.yahoo.comProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board AppointmentApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.February 28, 2023 | marketwatch.comAnaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029February 27, 2023 | marketwatch.comCompanion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029September 28, 2022 | marketwatch.comCompanion Diagnostics Market to show impressive growth of 11.04% CAGR during the period 2022-2027 | 102 Report PagesApril 16, 2022 | streetinsider.comForm DEF 14A Mirati Therapeutics, For: May 12 - StreetInsider.comMarch 31, 2022 | marketscreener.comFORTE BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.comApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.March 30, 2022 | newsweek.comWhat Is Glioblastoma? Aggressive Cancer Linked to Death of Tom Parker - NewsweekDecember 22, 2021 | seekingalpha.comWeek In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board - Seeking AlphaDecember 16, 2021 | finance.yahoo.comDenovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine - Yahoo FinanceSeptember 20, 2021 | washingtonpost.comChasing Cancer with Meg Kinnard - The Washington PostAugust 16, 2021 | marketscreener.comFORTE BIOSCIENCES, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.comSee More Headlines Receive TOCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tocagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/23/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TOCA CUSIPN/A CIK1419041 Webwww.tocagen.com Phone858-412-8400FaxN/AEmployees77Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,520,000.00 Net Margins-176,433.34% Pretax MarginN/A Return on Equity-327.74% Return on Assets-111.87% Debt Debt-to-Equity Ratio1.88 Current Ratio1.15 Quick Ratio1.15 Sales & Book Value Annual Sales$40,000.00 Price / Sales441.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book1.64Miscellaneous Outstanding Shares23,919,000Free FloatN/AMarket Cap$17.67 million OptionableNot Optionable Beta0.01 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Martin J. Duvall (Age 57)CEO & Director Mr. Thomas E. Darcy (Age 68)Co-Founder & Director Dr. Douglas J. Jolly (Age 71)Co-Founder and Exec. VP of Research & Pharmaceutical Devel. Mr. Mark G. Foletta C.P.A. (Age 58)CPA, Exec. VP & CFO Dr. Harry E. Gruber (Age 66)Founder, Adviser & Director Key CompetitorsVBI VaccinesNASDAQ:VBIVMinerva NeurosciencesNASDAQ:NERVBenitec BiopharmaNASDAQ:BNTCOrgenesisNASDAQ:ORGSFSD PharmaNASDAQ:HUGEView All Competitors TOCA Stock Analysis - Frequently Asked Questions How were Tocagen's earnings last quarter? Tocagen Inc (NASDAQ:TOCA) released its quarterly earnings data on Thursday, April, 23rd. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative trailing twelve-month return on equity of 327.74%. What other stocks do shareholders of Tocagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Selecta Biosciences (SELB), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), T2 Biosystems (TTOO), Amarin (AMRN), Novavax (NVAX), OPKO Health (OPK) and Amicus Therapeutics (FOLD). When did Tocagen IPO? Tocagen (TOCA) raised $80 million in an initial public offering on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO. This page (NASDAQ:TOCA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
